RECURSION PHARMACEUTICALS, INC.
10-K
February 25, 2026
Key Highlights
- First AI-enabled clinical proof of concept with REC-4881 successfully completing...
- Significant revenue growth to $155 million in 2025, primarily from strategic par...
- Secured over $500 million in non-dilutive payments from high-value partnerships ...
Read Analysis
🤖 AI Generated